Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Aikya. This analysis is provided for institutional research purposes only and is not investment advice.
"Aikya's Emerging Markets fund returned 5.0% in July, outperforming the benchmark by 8.1% as it declined 3.1%. The quality-focused strategy benefited from strength in Taiwan consumer names and Edge AI demand, Chinese internet platforms showing narrowing losses, and Indonesian banks delivering solid results."
Aikya's Global Emerging Markets Fund delivered a positive return of 5.0% in July 2026, significantly outperforming the MSCI Emerging Markets benchmark which declined 3.1%. The strategy's investment approach relies on two key pillars: Quality and Valuation, investing in high-quality companies at sensible valuations. The fund benefited from strength in information technology, consumer, and financial holdings. In Taiwan, Advantech benefited from firm demand for automation and Edge AI products, while Uni-President contributed as sentiment towards domestic consumer names improved. In China, Meituan improved following results that showed narrowing losses, and Foshan Haitian delivered strong results. Bank Central Asia in Indonesia delivered solid results, reassuring after a period of disfavour. EPAM recovered as IT Services disruption fears subsided. India was the main source of weakness, with Dr. Reddy's Laboratories softer and HDFC Bank under pressure, though both appear temporary. The fund holds 38 positions with 1.3% cash, concentrated in Consumer Staples (38.5%) and Financials (19.7%).
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.